Pharmaron Beijing revenue and financials
¥44.97Change from previous close: +4.63%Absolute change: +¥1.99
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 14,095 | 12,276 | 11,538 | 10,266 | — |
| Cost of revenue | 9,185 | 8,073 | 7,414 | 6,498 | — |
| Gross profit | 4,910 | 4,203 | 4,124 | 3,768 | — |
| Selling, general and administrative | 789 | 721 | 802 | 779 | — |
| Research and development | 576 | 469 | 448 | 282 | — |
| Operating income | 2,225 | 1,864 | 1,833 | 1,751 | — |
| EBIT | 2,106 | 2,335 | 2,020 | 1,834 | — |
| EBITDA | 3,286 | 3,384 | 2,947 | 2,530 | — |
| Interest expense | 193 | 244 | 182 | 167 | — |
| Pre-tax income | 1,913 | 2,091 | 1,838 | 1,666 | — |
| Income tax | 358 | 377 | 256 | 314 | — |
| Net income | 1,664 | 1,793 | 1,601 | 1,375 | — |
| Net income to common shareholders | 1,664 | 1,793 | 1,601 | 1,375 | — |
| Basic EPS | 0.94 | 1.01 | 0.90 | 0.78 | — |
| Diluted EPS | 0.94 | 1.01 | 0.90 | 0.77 | — |
| Average shares (basic) | 1,762 | 1,770 | 1,772 | 1,774 | — |
| Average shares (diluted) | 1,771 | 1,773 | 1,775 | 1,776 | — |